Organoids: Opportunities and Challenges of Cancer Therapy

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2023 Aug 14

PMID 37576596

Authors

Xianjie Jiang

Linda Oyang

Qiu Peng

Qiang Liu

Xuemeng Xu

Nayiyuan Wu

Shiming Tan

Wenjuan Yang

Yaqian Han

Jinguan Lin

Longzheng Xia

Mingjing Peng

Yanyan Tang

Xia Luo

Min Su

Yingrui Shi

Yujuan Zhou

Qianjin Liao

Affiliations

Soon will be listed here.

Abstract

Organoids are a class of multicellular structures with the capability of self-organizing and the characteristic of original tissues, they are generated from stem cells in 3D culture . Organoids can mimic the occurrence and progression of original tissues and widely used in disease models in recent years. The ability of tumor organoids to retain characteristic of original tumors make them unique for tumorigenesis and cancer therapy. However, the history of organoid development and the application of organoid technology in cancer therapy are not well understood. In this paper, we reviewed the history of organoids development, the culture methods of tumor organoids establishing and the applications of organoids in cancer research for better understanding the process of tumor development and providing better strategies for cancer therapy. The standardization of organoids cultivation facilitated the large-scale production of tumor organoids. Moreover, it was found that combination of tumor organoids and other cells such as immune cells, fibroblasts and nervous cells would better mimic the microenvironment of tumor progression. This might be important developing directions for tumor organoids in the future.

Citing Articles

Patient-Derived Tumor Organoids: A Platform for Precision Therapy of Colorectal Cancer.

Li Y, Wu W, Yao J, Wang S, Wu X, Yan J Cell Transplant. 2025; 34:9636897251314645.

PMID: 39953837 PMC: 11829288. DOI: 10.1177/09636897251314645.

Exploring oncology treatment strategies with tyrosine kinase inhibitors through advanced 3D models (Review).

Isinelli G, Failla S, Plebani R, Prete A Med Int (Lond). 2025; 5(2):13.

PMID: 39790707 PMC: 11707505. DOI: 10.3892/mi.2024.212.

Generation and maintenance of kidney and kidney cancer organoids from patient-derived material for drug development and precision oncology.

Gubala J, Mieville V, Benamran D, Tille J, Valerio M, Nowak-Sliwinska P Mol Ther Methods Clin Dev. 2024; 32(4):101368.

PMID: 39659758 PMC: 11629258. DOI: 10.1016/j.omtm.2024.101368.

Breaking the mold: 3D cell cultures reshaping the future of cancer research.

Cordeiro S, Oliveira B, Valente R, Ferreira D, Luz A, Baptista P Front Cell Dev Biol. 2024; 12:1507388.

PMID: 39659521 PMC: 11628512. DOI: 10.3389/fcell.2024.1507388.

Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy.

Logun M, Wang X, Sun Y, Bagley S, Li N, Desai A Cell Stem Cell. 2024; 32(2):181-190.e4.

PMID: 39657679 PMC: 11808387. DOI: 10.1016/j.stem.2024.11.010.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Muthusamy T, Cordes T, Handzlik M, You L, Lim E, Gengatharan J . Serine restriction alters sphingolipid diversity to constrain tumour growth. Nature. 2020; 586(7831):790-795. PMC: 7606299. DOI: 10.1038/s41586-020-2609-x. View

Byrne A, Alferez D, Amant F, Annibali D, Arribas J, Biankin A . Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer. 2017; 17(4):254-268. DOI: 10.1038/nrc.2016.140. View

Yoshida T, Sopko N, Kates M, Liu X, Joice G, McConkey D . Three-dimensional organoid culture reveals involvement of Wnt/β-catenin pathway in proliferation of bladder cancer cells. Oncotarget. 2018; 9(13):11060-11070. PMC: 5834271. DOI: 10.18632/oncotarget.24308. View

Boretto M, Maenhoudt N, Luo X, Hennes A, Boeckx B, Bui B . Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. Nat Cell Biol. 2019; 21(8):1041-1051. DOI: 10.1038/s41556-019-0360-z. View

Zhao H, Jiang E, Shang Z . 3D Co-culture of Cancer-Associated Fibroblast with Oral Cancer Organoids. J Dent Res. 2020; 100(2):201-208. DOI: 10.1177/0022034520956614. View

Boretto M, Cox B, Noben M, Hendriks N, Fassbender A, Roose H . Development of organoids from mouse and human endometrium showing endometrial epithelium physiology and long-term expandability. Development. 2017; 144(10):1775-1786. DOI: 10.1242/dev.148478. View

Gao D, Vela I, Sboner A, Iaquinta P, Karthaus W, Gopalan A . Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014; 159(1):176-187. PMC: 4237931. DOI: 10.1016/j.cell.2014.08.016. View

Xia X, Li F, He J, Aji R, Gao D . Organoid technology in cancer precision medicine. Cancer Lett. 2019; 457:20-27. DOI: 10.1016/j.canlet.2019.04.039. View

10.

Lu S, Yan D, Wu Z, Jiang T, Chen J, Yuan L . Ubiquitin-like with PHD and ring finger domains 2 is a predictor of survival and a potential therapeutic target in colon cancer. Oncol Rep. 2014; 31(4):1802-10. DOI: 10.3892/or.2014.3035. View

11.

Kondo J, Inoue M . Application of Cancer Organoid Model for Drug Screening and Personalized Therapy. Cells. 2019; 8(5). PMC: 6562517. DOI: 10.3390/cells8050470. View

12.

Ward R, Fawell S, Floch N, Flemington V, McKerrecher D, Smith P . Challenges and Opportunities in Cancer Drug Resistance. Chem Rev. 2020; 121(6):3297-3351. DOI: 10.1021/acs.chemrev.0c00383. View

13.

Unbekandt M, Davies J . Dissociation of embryonic kidneys followed by reaggregation allows the formation of renal tissues. Kidney Int. 2009; 77(5):407-16. DOI: 10.1038/ki.2009.482. View

14.

Driehuis E, Van Hoeck A, Moore K, Kolders S, Francies H, Gulersonmez M . Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc Natl Acad Sci U S A. 2019; 116(52):26580-26590. PMC: 6936689. DOI: 10.1073/pnas.1911273116. View

15.

Chakrabarti J, Koh V, So J, Yong W, Zavros Y . A Preclinical Human-Derived Autologous Gastric Cancer Organoid/Immune Cell Co-Culture Model to Predict the Efficacy of Targeted Therapies. J Vis Exp. 2021; (173). DOI: 10.3791/61443. View

16.

Workman M, Mahe M, Trisno S, Poling H, Watson C, Sundaram N . Engineered human pluripotent-stem-cell-derived intestinal tissues with a functional enteric nervous system. Nat Med. 2016; 23(1):49-59. PMC: 5562951. DOI: 10.1038/nm.4233. View

17.

Bellapianta A, Cetkovic A, Bolz M, Salti A . Retinal Organoids and Retinal Prostheses: An Overview. Int J Mol Sci. 2022; 23(6). PMC: 8953078. DOI: 10.3390/ijms23062922. View

18.

Calandrini C, van Hooff S, Paassen I, Ayyildiz D, Derakhshan S, Dolman M . Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors. Cell Rep. 2021; 36(8):109568. DOI: 10.1016/j.celrep.2021.109568. View

19.

Garreta E, Kamm R, Chuva de Sousa Lopes S, Lancaster M, Weiss R, Trepat X . Rethinking organoid technology through bioengineering. Nat Mater. 2020; 20(2):145-155. DOI: 10.1038/s41563-020-00804-4. View

20.

Lee S, Hu W, Matulay J, Silva M, Owczarek T, Kim K . Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell. 2018; 173(2):515-528.e17. PMC: 5890941. DOI: 10.1016/j.cell.2018.03.017. View